Pfizer halts Phase 2 trial of PF-06835375 in primary immune thrombocytopenia

Pfizer announced that it is stopping its Phase 2 study of the experimental program PF-06835375, which was being evaluated in patients with primary immune thrombocytopenia, a rare autoimmune blood disorder.

The decision to halt the trial was recorded in the federal clinical trials database, but no specific safety or efficacy concerns were disclosed in the brief report. The termination suggests a setback for the candidate’s development timeline and may affect expectations for future data from the program.

In unrelated news, biotech firm Lycia Therapeutics is targeting a $227 million initial public offering, signaling its intent to raise capital for ongoing and upcoming projects.